Candel Therapeutics (NASDAQ: CADL)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-09-07 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.310 | -0.300 | 0.0100 | ||||
REV | 31.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Candel Therapeutics (NASDAQ: CADL) through any online brokerage.
Other companies in Candel Therapeutics’s space includes: Anixa Biosciences (NASDAQ:ANIX), Fortress Biotech (NASDAQ:FBIO), HOOKIPA Pharma (NASDAQ:HOOK), Ambrx Biopharma (NYSE:AMAM) and Curis (NASDAQ:CRIS).
The latest price target for Candel Therapeutics (NASDAQ: CADL) was reported by BMO Capital on Thursday, March 31, 2022. The analyst firm set a price target for 12.00 expecting CADL to rise to within 12 months (a possible 273.83% upside). 5 analyst firms have reported ratings in the last year.
The stock price for Candel Therapeutics (NASDAQ: CADL) is $3.21 last updated July 1, 2022, 8:00 PM UTC.
There are no upcoming dividends for Candel Therapeutics.
Candel Therapeutics’s Q2 earnings are confirmed for Wednesday, September 7, 2022.
There is no upcoming split for Candel Therapeutics.
Candel Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.